A Regulatory Blind Spot Hiding in Plain Sight
By JUSTIN MCKAY When I’m brought back into the diagnostic area, one of the first…
By JUSTIN MCKAY When I’m brought back into the diagnostic area, one of the first things I see is a lead apron, well-worn and folded into itself, about ready to slide off the table where it was absentmindedly placed. For many people, this sight would not be startling, but I know firsthand the life-threatening dangers…
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition. The post Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder appeared first on MedCity…
Allswell’s seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures. The post Allswell Raises $7M to Grow LGBTQ+ Behavioral Health Platform appeared first on MedCity News.
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on. The post The Antibiotics Exist —The System Cannot Deliver Them appeared first on MedCity News.
Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good advice into usable care. The post Exercise is Prescribed Like Advice When It Should Be Delivered Like Treatment appeared first on MedCity News.
UPMC Enterprises is making a strategic investment in VeloSource with plans to further develop its AI-enabled staffing management platform. The post UPMC Enterprises Invests in VeloSource to Expand AI-Enabled Clinician Staffing Platform appeared first on MedCity News.
Epic will launch a tool in summer 2027 to help patients compare prescription cash prices and insurance costs across pharmacies. The post Why Epic Is Launching a Prescription Price Comparison Tool appeared first on MedCity News.
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders. The post City Therapeutics’ Upsized IPO Raises $200M…
Chris Johnson, founder and CEO of Bluebird Kids Health, talks about building clinics in Florida with a focus on value-based care arrangements
Addressing digital harms in healthcare requires collaboration among stakeholders, with a focus on integrating patient voices into system design, governance, and accountability